Interius BioTherapeutics develops in vivo lentivector gene therapies specifically targeting B cell lymphomas, utilizing programmable vectors for precise genetic medicine delivery. The company aims to provide effective treatment options for patients with challenging hematological malignancies, addressing the need for targeted therapies in oncology.
Funding
$144.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
B-cell lymphomas present significant treatment challenges, and there is a need for more targeted therapies to improve patient outcomes. Traditional treatment options may have limited efficacy or significant side effects, highlighting the need for innovative approaches.
Solution
Interius BioTherapeutics is developing in vivo lentivector gene therapies designed for precise genetic medicine delivery, specifically targeting B-cell lymphomas. Their proprietary LENTIVECTOR platform engineers targeted, programmable vectors to deliver genetic medicines directly within the body. This approach aims to provide more effective treatment options for patients with challenging hematological malignancies, offering a new generation of genetic medicines with best-in-class therapeutic potential in oncology and autoimmunity. The company's pipeline includes novel lentivector therapeutics that leverage multidisciplinary knowledge to address unmet medical needs and improve accessibility to advanced therapies.
Target Audience
The primary target audience includes patients with B-cell malignancies, as well as healthcare providers and clinical researchers focused on innovative cancer therapies.
Features
- Proprietary LENTIVECTOR platform for targeted in vivo gene therapy
- Programmable vectors for precision delivery of genetic medicines
- Pipeline of novel lentivector therapeutics for oncology and autoimmunity
- Focus on in vivo CAR (Chimeric Antigen Receptor) gene therapy for B-cell malignancies
- Clinical trials underway for first-in-class in vivo CAR therapeutic